MagDI con manga gástrica explicado | Imanes en lugar de grapas: una alternativa más segura al SADI-S y al cruce duodenal

This may be the biggest innovation in bariatric surgery since the sleeve gastrectomy — a magnetic anastomosis that forms itself, without cutting the bowel. It's the MagDI — which stands for magnetic duodeno-ileostomy. It uses magnets instead of staples or sutures to create an intestinal connection. When combined with a sleeve gastrectomy, it achieves the metabolic power of a duodenal switch — but without cutting or dividing the intestine.

The concept is simple. Two small magnets are placed inside the duodenum and the distal ileum. They attract each other through the bowel walls, gradually compress the tissue between them, and form a natural, living connection over two weeks. The magnets then detach and pass on their own. No bowel incision. No staples. No sutures at the anastomosis.

The first human MagDI procedures were performed in late 2021. Since then, multicenter studies across Europe, the Middle East, and the Americas have demonstrated that the procedure is feasible, safe, and effective.

If you have watched our videos on the SADI-S and the Roux duodenal switch, you already know those operations. Throughout this video, I will compare MagDI directly to both — because understanding the differences is how you and your surgeon choose the right procedure. Let us get into it.

Who Qualifies?

Current ASMBS guidelines recommend metabolic surgery for BMI 35 or higher regardless of other conditions, BMI 30 to 35 with metabolic disease like diabetes or sleep apnea.

MagDI plus sleeve is especially well suited for three groups. First, patients with type 2 diabetes — because the intestinal rerouting produces powerful metabolic effects. Second, patients who have already had a sleeve gastrectomy and need additional weight loss or diabetes control — MagDI can be added as a second-stage procedure without redoing the sleeve. Third, patients who want the metabolic benefits of a duodenal switch but prefer a less invasive intestinal connection.

In clinical practice, MagDI plus sleeve has been performed in patients with BMI ranging from 30 to well above 50.

The Procedure: How MagDI Differs from the SADI-S and Roux DS

All three operations — MagDI plus sleeve, SADI-S, and Roux DS — combine a sleeve gastrectomy with an intestinal connection that delivers food to the distal ileum. The sleeve portion is identical. The differences are in how the intestinal connection is created, whether the duodenum is divided, and how food flows after surgery. These three differences change everything.

The sleeve gastrectomy is the same in all three operations. We remove about 75 to 85 percent of the stomach including the fundus. The pylorus is preserved. Now here is where MagDI diverges from both the SADI-S and the Roux DS.

Difference one: how the connection is created.

In the SADI-S, the intestinal connection is stapled or hand-sewn — one anastomosis. In the Roux DS, two connections are stapled or hand-sewn. In MagDI, the connection is formed by magnetic compression. A magnet is delivered into the first part of the duodenum.

A second magnet is inserted into the distal ileum, approximately 250 centimeters from the ileocecal valve. The magnets align through the bowel walls, compress the tissue between them, and over two weeks the compressed tissue breaks down naturally and a living, mucosal-lined connection forms. The magnets detach and pass naturally at a median of 37 to 48 days. No bowel incision.

No stapler fired. No sutures at the anastomosis site. This essentially eliminates the risk of anastomotic leak from a staple or suture line — the most feared early complication of any intestinal connection. In the largest multicenter study of 43 patients, there were zero device-related anastomotic leaks.

Difference two: whether the duodenum is divided. In both the SADI-S and the Roux DS, the duodenum is transected — cut completely — about two to three centimeters below the pylorus. Food is forced entirely through the bypass. In MagDI, the duodenum is never divided. It stays intact. The magnetic connection creates a side-to-side opening — a new pathway — but the original pathway through the duodenum remains open.

This is the single biggest anatomical difference between MagDI and every other duodenal switch procedure. Difference three: how food flows after surgery. In the SADI-S, food travels exclusively through the loop limb to the common channel. In the Roux DS, food travels exclusively through the alimentary limb to the common channel. In both, the duodenum is excluded.

In MagDI, food has two pathways. Some of the meal transits directly through the magnetic connection into the distal ileum, while the remainder continues through the normal duodenal route. This is called bipartition — the food stream is split, not completely rerouted.

This dual-pathway design means you get significant ileal stimulation and hormonal benefit, but you also maintain normal duodenal transit. Bile and pancreatic enzymes still mix with food in the duodenum. Endoscopic access to the biliary and pancreatic systems is preserved — after a SADI-S or Roux DS, accessing the biliary tree drainage point endoscopically is extremely difficult or impossible.

The procedure takes about 90 to 160 minutes when combined with a sleeve. When MagDI is added after a prior sleeve, the MagDI portion alone takes about 50 to 75 minutes. Most patients stay one to two nights and return to normal activities within two to four weeks.

How It Works

MagDI plus sleeve works through the same core mechanisms as the SADI-S and Roux DS — restriction, ghrelin reduction, GLP-1 and PYY surge, improved insulin sensitivity, and reduced calorie absorption. The sleeve limits how much you can eat. Removing the fundus dramatically reduces ghrelin. Delivering food to the distal ileum triggers a powerful surge in GLP-1 and PYY — the same hormonal changes that make the SADI-S and Roux DS so effective for diabetes.

The key physiological difference is the degree of malabsorption. Because the duodenum is not divided and food still passes through the normal digestive pathway, MagDI produces less malabsorption than either the SADI-S or the Roux DS. This is a deliberate trade-off: less malabsorption means fewer nutritional complications and less diarrhea, but potentially slightly less maximum weight loss in the highest BMI patients.

Early comparative data from surgical transit bipartition — the same concept as MagDI but with a sutured connection — support this. Frequent loose stools occurred in only 7 percent of bipartition patients versus 33 percent after the Roux DS. Surgical reintervention for malnutrition or side effects was needed in only 4 percent versus 10 percent.

Results

MagDI plus sleeve is a newer procedure, so the data come from prospective multicenter studies with follow-up ranging from one to four years. The results so far are very encouraging — and comparable to the SADI-S and Roux DS at the same time points.

Weight loss with concurrent MagDI plus sleeve: at 12 months, total weight loss reached 34 percent and excess weight loss reached 80 percent. One Spanish center reported 39 percent total weight loss and 83 percent excess weight loss at one year. A Canadian multicenter study of a similar magnetic anastomosis technique with concurrent sleeve reported 31 percent total weight loss and 78 percent excess weight loss at 12 months.

For comparison, the SADI-S produces 34 to 40 percent total weight loss at one year. The Roux DS produces 35 to 40 percent. At one year, MagDI is in the same range. Weight loss with MagDI added after a prior sleeve: results are more modest — 8 kilograms of additional weight loss and 17 percent excess weight loss at 6 months. This is expected, because the hormonal reset from the original sleeve has already occurred.

Diabetes improvement has been dramatic. In the first-in-human MagDI study, HbA1c dropped from 8.2 percent to 6.6 percent at one year. In the combined MagDI plus sleeve cohort, HbA1c dropped from 6.8 percent to 4.8 percent and fasting glucose dropped by 47 mg/dL at 12 months. The Canadian study reported complete type 2 diabetes remission in 78 percent at one year, with 100 percent achieving HbA1c at or below 6.0 percent.

For comparison, the SADI-S achieves diabetes remission in 60 to 93 percent. The Roux DS achieves 85 to 93 percent. MagDI is competitive at one year. Four-year data from a related magnetic anastomosis technique showed sustained glycemic improvement, with HbA1c decreasing from 8.3 percent to 6.9 percent at 48 months.

Longer-term weight data come from surgical transit bipartition — the same concept with a sutured connection. A large series of over 1,000 patients showed excess BMI loss of 91 percent at one year and 74 percent at five years. A medium-term comparative study of bipartition versus Roux DS in patients with BMI over 50 showed that by five years the difference was no longer statistically significant — bipartition achieved 43 percent total weight loss versus 45 percent for the Roux DS.

Risks and Complications

The safety profile of MagDI plus sleeve has been excellent in early studies.

In the largest multicenter study of 43 patients, there were zero device-related adverse events — no anastomotic leakage, bleeding, obstruction, infection, or death related to the magnet system. Most adverse events were mild. In the first-in-human study of 15 patients, feasibility was confirmed in 100 percent with zero leakage, bleeding, infection, stricture, or mortality. Anastomosis patency has been confirmed at 100 percent in all studies at 12 months and beyond.

In the Italian multicenter study of 28 patients, there were three serious adverse events: one ileal perforation on postoperative day one, one case of liver insufficiency requiring reversal at day 144, and one trocar site hernia. Early complications include the standard risks of sleeve gastrectomy — staple line leak in 1 to 2 percent, bleeding in 1 to 6 percent.

Long-term nutritional risk is expected to be significantly lower than the SADI-S or Roux DS because duodenal continuity is preserved. The comparative data from surgical bipartition support this: protein malnutrition requiring reintervention occurred in only 4 percent versus 10 percent after the Roux DS. Diarrhea occurred in 7 percent versus 33 percent. Fat-soluble vitamin monitoring is still recommended, but the deficiency rates are expected to be lower than the 53.5 percent seen with the Roux DS or the 15.6 percent seen with the SADI-S at 10 years.

GERD may occur after the sleeve component, as with any sleeve gastrectomy. It is important to emphasize: MagDI plus sleeve is still an emerging procedure. Long-term data beyond four years are limited. The safety and efficacy profile will continue to be defined as larger studies with longer follow-up are completed.

The Bottom Line: MagDI vs SADI-S vs Roux DS

All three procedures combine a sleeve with intestinal rerouting to the distal ileum. All three produce powerful weight loss and metabolic effects. The differences are in the details.

MagDI advantages over SADI-S and Roux DS: no bowel division — the duodenum stays intact. No stapled or sutured anastomosis — zero anastomotic leaks in clinical studies. Preserved dual-pathway food flow with less malabsorption. Fewer nutritional complications and less diarrhea. Preserved endoscopic access to the biliary system. Potentially reversible — the magnetic connection can theoretically be closed.

SADI-S advantages over MagDI: endorsed by IFSO and ASMBS with 10-plus years of data. Proven long-term durability. Complete intestinal rerouting may produce slightly more weight loss in the highest BMI patients. Roux DS advantages over MagDI: eliminates bile reflux entirely. Longest track record with 20-plus years of data. Greatest proven long-term weight loss in super-obese patients.

MagDI trade-offs: limited long-term data — the procedure has only been performed since 2021. Smaller study populations. The bipartition physiology may produce slightly less maximum weight loss than complete rerouting in patients with very high BMI, though the five-year bipartition data show no statistically significant difference.

Life After Surgery

Diet progresses in stages — clear liquids, purees, soft foods, and regular food by six to eight weeks. Protein first — at least 60 to 80 grams per day.

Because MagDI preserves duodenal continuity, the vitamin requirements are expected to be less intensive than after the SADI-S or Roux DS — but they are still essential. You will need a bariatric multivitamin, calcium citrate at 1,200 to 1,500 milligrams per day, vitamin D adjusted to blood levels, B12, iron especially for premenopausal women, and fat-soluble vitamins A, E, and K monitored and supplemented as needed.

Blood work every three to six months in the first year, then at least annually for life. Even though the nutritional risk is lower, do not skip your vitamins or your follow-up. Build to at least 150 minutes of exercise per week. In clinical studies, 70 percent of patients reported being very satisfied at one year.

Final Thoughts

MagDI plus sleeve gastrectomy represents a new frontier in metabolic surgery. It delivers the hormonal power of a duodenal switch — without cutting the bowel, without stapling the anastomosis, and without dividing the duodenum. Early data show excellent weight loss and diabetes improvement with a favorable safety profile and fewer nutritional complications than either the SADI-S or the Roux DS.

But it is still a newer procedure. Long-term data are still being collected. And like any bariatric surgery, it requires lifelong commitment to your vitamins, your nutrition, your activity, and your follow-up. If you are considering this procedure, the next step is a consultation. We will look at your individual situation and help you decide whether MagDI plus sleeve, the SADI-S, the Roux DS, or another procedure is the right fit.

You deserve a life that feels bigger than your weight, and we are here to help you get there. Thank you for watching. Real science. Real surgery. Real results.